Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder

Objective: To further define the efficacy and safety profiles of lisdexamfetamine dimesylate (LDX) in Japanese pediatric patients with attention-deficit/hyperactivity disorder (ADHD). Methods: This was a multicenter, randomized, double-blind, placebo-controlled study of LDX 30, 50, or 70 mg/day for...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Child Adolesc Psychopharmacol
Autors principals: Ichikawa, Hironobu, Miyajima, Tasuku, Yamashita, Yushiro, Fujiwara, Masakazu, Fukushi, Akimasa, Saito, Kazuhiko
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc., publishers 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7041327/
https://ncbi.nlm.nih.gov/pubmed/31718254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2019.0076
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars